预约演示

Merz wins $185m bid for bankrupt Acorda assets and increases US workforce by 50%

2024-07-11

交易

并购引进/卖出上市批准

Fampyra used to see sales of over $500m in 2017, but sales weakened after generics entered the market. Image credit: Shutterstock / Elena Abrazhevich.

Merz Therapeutics has successfully acquired Acorda’s Inbrija (levodopa inhalation powder) and Ampyra (dalfampridine) after the latter went bankrupt earlier this year.

Merz Therapeuticsa “stalking horse” bid, meaAcordahe Inbrijacould have gone for more than the AmpyraopdalfampridineMerz. These types of bids are used in cases involving bankrupt companies. No competing company joined the auction, however, and Merz closed the transaction at the opening bid value.

Merz said the addition of Inbrija and Ampyra, the latter marketed as Fampyra (fampridine) outside of the US, would Merzediately add topline revenue” and enhance the biotech’s ability to expedite clinical development of other assets, as per a 1Merzly press release.

Merz’s lead product is XeoInbrija InbrijacobotAmpyratoxinA), used to treat exFampyra dfampridinepper limb spasticity, and cervical dystonia, among others. Inbrija meanwhile is used to treat patients with Parkinson’s disease while Ampyra / Fampyra is approved to help improve walking ability in patients with multiple sclerosis.

Merz CEO Stefan König sXeomine incobotulinumtoxinAthe company’s] maexcessive droolingarupper limb spasticityle “excervical dystoniamultiple sclerosInbrijaent”.Parkinson’s disease Ampyra Fampyra multiple sclerosis

MerzAlso:BARDA and Tiba Biotech link to develop ‘flu therapeuticsParkinson’s disease multiple sclerosis

Can a ‘suBARDAill’ Tiba BiotechBig Pharma’s climate footprint?

Merz also expects to increase its US workforce by more than 50% to support the newly added assets.

Inbrija and Fampyra generated global sales of $31m and $73m, respectively, last year. According to GlobalData’s Pharma Intelligence Centre, Fampyra used to see sales of over $500m in 2017. But once it lost exclusivity in 2018, generics flooded the market, and sales weakened.

GlobalData is the parent company of Pharmaceutical Technology.

Merz forecasts its US business to contribute more than 75% of total global revenues for Inbrija and Fampyra over the next decade.

Inbrija Inbrijaused Fampyra big player in the neurodegenerative disorder space up until a few years ago. The formerly liPharma Intelligence CentrehaFampyra to spare when it decided to acquire Finnish biopharma Biotie Therapies, a developer of Parkinson’s disease therapies, in 2016.

However, in subsequent years, AcordaPharmaceutical Technology sales of its drugs weakened. Biogen, which had a 2009 licence agreement for Fampyra outside the US, returned the rights to Acorda earlier this year. Shares in the company continued to dive and Acorda ultimately filed for bankruptcy, announced via a 1 April press release.

Merzddition, Acorda was delisted from the Nasdaq Stock Market in mid-April, and closed iInbrijas for the final time last month, leaving 97 employees at its New York site out of work.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构